Real world Indian experience of switchover to Bilastine in CSU patient refractory to other antihistamines
Background: Second generation anti histamines are first line therapy as recommended by many guidelines for Chronic spontaneous urticaria (CSU). Bilastine, non-sedative H1-antihistamine is recently approved in India for the management of CSU.
Materials and Methods: A real world retrospective study was conducted across India to assess the response of CSU patients who were switched over to bilastine after non satisfactory response to other antihistamines at 140 dermatology clinics.
Results: A data of 518 patients’ were included in this analysis. Mean age of the patients was 35.3 12.3 years while mean disease duration was 7.089.3 months. Baseline mean UCT score of 8.6 3.02 was improved to 13.05 2.9 in 28 days (p
Conclusion: Authors concluded that in patients with inadequate response to commonly used antihistamines at licensed dose, switch over to bilastine resulted, not only in reliving the symptoms of CSU but also added to the Patients’ satisfaction with the drug.
Keywords: Bilastine, Urticaria antihistamines, Real world, Refractory.
Materials and Methods: A real world retrospective study was conducted across India to assess the response of CSU patients who were switched over to bilastine after non satisfactory response to other antihistamines at 140 dermatology clinics.
Results: A data of 518 patients’ were included in this analysis. Mean age of the patients was 35.3 12.3 years while mean disease duration was 7.089.3 months. Baseline mean UCT score of 8.6 3.02 was improved to 13.05 2.9 in 28 days (p
Conclusion: Authors concluded that in patients with inadequate response to commonly used antihistamines at licensed dose, switch over to bilastine resulted, not only in reliving the symptoms of CSU but also added to the Patients’ satisfaction with the drug.
Keywords: Bilastine, Urticaria antihistamines, Real world, Refractory.